Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.
Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.
Leishmaniasis, Impact and Therapeutic Needs; Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives; From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis; Drug Assay Methodology in Leishmaniasis: From the Microplate to Image Analysis; The Pursuit of Novel Anti-leishmanial Agents by High-throughput Screening (HTS) of Chemical Libraries; Omics and Their Impact on the Development of Chemotherapy Against Leishmania; In silico Tools for Target Identification and Drug Molecular Docking in Leishmania; Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs; Natural Products as a Source of New Drugs Against Leishmania; Organometallic Compounds in Chemotherapy Against Leishmania; New Avenues for Drug Delivery in Leishmania: Using Treatment of Visceral Leishmaniasis with Amphotericin B as an Exemplar; Addressing the Molecular Biology of Leishmania for Drug Development; The Physical Matrix of the Plasma Membrane as a Target: The Charm of Drugs with Low Specificity; Nutrient Transport and Sensing as Pharmacological Targets for Leishmaniasis; Carbon Metabolism as a Drug Target in Leishmania; The Redox Metabolism and Oxidative Stress in Leishmania as a Crossroads for the Lethal Effect of Drugs; DNA Topoisomerases as Promising Targets for Leishmania Chemotherapy; Molecular Basis of Drug Resistance in Leishmania; The Macrophage-Parasite Interface as a Chemotherapeutic Target in Leishmaniasis
Leishmaniasis, Impact and Therapeutic Needs; Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives; From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis; Drug Assay Methodology in Leishmaniasis: From the Microplate to Image Analysis; The Pursuit of Novel Anti-leishmanial Agents by High-throughput Screening (HTS) of Chemical Libraries; Omics and Their Impact on the Development of Chemotherapy Against Leishmania; In silico Tools for Target Identification and Drug Molecular Docking in Leishmania; Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs; Natural Products as a Source of New Drugs Against Leishmania; Organometallic Compounds in Chemotherapy Against Leishmania; New Avenues for Drug Delivery in Leishmania: Using Treatment of Visceral Leishmaniasis with Amphotericin B as an Exemplar; Addressing the Molecular Biology of Leishmania for Drug Development; The Physical Matrix of the Plasma Membrane as a Target: The Charm of Drugs with Low Specificity; Nutrient Transport and Sensing as Pharmacological Targets for Leishmaniasis; Carbon Metabolism as a Drug Target in Leishmania; The Redox Metabolism and Oxidative Stress in Leishmania as a Crossroads for the Lethal Effect of Drugs; DNA Topoisomerases as Promising Targets for Leishmania Chemotherapy; Molecular Basis of Drug Resistance in Leishmania; The Macrophage-Parasite Interface as a Chemotherapeutic Target in Leishmaniasis
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
